| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 3,097.0 | 2,816.0 |
| Profit before tax | 416.0 | 328.0 |
| Net income | 312.0 | 245.0 |
| EPS (diluted, $ a share) | $2.78 | $2.16 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +27.3% |
|---|---|
| Revenue, year on year | +10.0% |
| Operating margin | 15.5% |
10-Q filed with the SEC, NYSE: DGX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Quest Diagnostics Inc: key numbers
- Share price
- $262.21Close, Nov 16
- Market cap
- $28.8B
- Shares outstanding
- 110.02MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Medical LaboratoriesSIC 8071
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Quest Diagnostics Inc
All →Quest Diagnostics SVP for Diagnostic Services Patrick Plewman Sells $3.02M of Stock
Patrick Plewman, SVP for Diagnostic Services, sold 11,717 shares of Quest Diagnostics Inc at $257.34 a share, worth $3.02M in total on Nov 9, 2026. Shares held after the trade: 14,684 (-4.2%).
- Value
- $3.02M
- Shares
- 11,717
- Average price
- $257.34
- Role
- SVP for Diagnostic Services
- Holding change
- -4.2%
- Trade date
- Nov 9, 2026
Quest Diagnostics EVP Catherine T. Doherty Sells $5.48M of Stock
Catherine T. Doherty, EVP, sold 22,105 shares of Quest Diagnostics Inc at $245.45 to $251.24 a share (average $248.02) in 7 transactions, worth $5.48M in total on Nov 3, 2026. Shares held after the trade: 71,949 (-3.9%).
- Value
- $5.48M
- Shares
- 22,105
- Average price
- $248.02
- Role
- EVP
- Holding change
- -3.9%
- Trade date
- Nov 3, 2026
Quest Diagnostics Insider Gary M. Pfeiffer Sells $292K of Stock
Gary M. Pfeiffer sold 1,203 shares of Quest Diagnostics Inc at $243.00 a share, worth $292K in total on Oct 26, 2026. Shares held after the trade: 29,802 (-3.9%).
- Value
- $292K
- Shares
- 1,203
- Price
- $243.00
- Holding change
- -3.9%
- Trade date
- Oct 26, 2026
Quest Diagnostics Cybersecurity Incident
Quest Diagnostics disclosed a cybersecurity incident involving unauthorized access to its Quanum LSM system, which clients use for test orders and results. The company believes an unauthorized party accessed certain patient records and has notified federal law enforcement. The incident has not materially disrupted business operations or the company's ability to serve patients.
Quest Diagnostics Financial Results
Quest Diagnostics reported third quarter 2026 revenues of $3.10 billion, a 10% increase year-over-year driven by strong organic growth across physician, hospital, and consumer channels. The company raised its full-year 2026 guidance for both revenue and EPS, citing productivity gains from automation and AI and expanding clinical care needs.
- Term
- Q3 2026
“We delivered revenue growth of 10% and adjusted EPS growth of over 15% on continued strength across our physician, hospital and consumer channels, complemented by productivity gains from automation and AI. Our robust organic revenue growth demonstrates that our solutions are fulfilling the expanding clinical care needs of an aging population as well as the increasing number of people focused on prevention and wellness. With these growth trends and our strong performance, we are raising our revenue and EPS guidance for the full year.”
Jim Davis, Chairman, CEO and President
Quest Diagnostics Leadership Change
Quest Diagnostics announced that Catherine T. Doherty will retire in July 2027, transitioning to a new role as Executive Vice President effective November 1, 2026. In her new role, she will oversee health systems, a joint venture with Corewell Health, and the Project Nova modernization initiative while maintaining her current base salary and receiving a $1.2 million RSU grant.
- Term
- through July 2027